DEMADEX by Roche is clinical pharmacology mechanism of action micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of henle, where it inhibits the na/k/2ci-carrier system. Approved for edema associated with congestive heart failure, renal disease, hepatic disease and 2 more indications. First approved in 1993.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
DEMADEX (torsemide) is a loop diuretic that inhibits the Na/K/2Cl-carrier system in the thick ascending portion of the loop of Henle, increasing urinary excretion of sodium, chloride, and water. It is indicated for edema associated with congestive heart failure, renal disease, hepatic disease, and hypertension as monotherapy or adjunctive agent. The drug's diuretic activity correlates with urinary excretion rate rather than serum concentration.
Product approaching loss of exclusivity with modest competitive pressure (30/100), suggesting defensive brand strategy and potential team restructuring ahead.
CLINICAL PHARMACOLOGY Mechanism of Action Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na/K/2CI-carrier system. Clinical pharmacology studies have confirmed this site of action in…
Worked on DEMADEX at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DEMADEX as a professional offers experience in mature product stewardship, competitive pricing defense, and customer retention in a commodity market. Career growth is limited by LOE dynamics; role stability depends on Roche's strategic commitment to the cardiovascular/renal therapeutic area.